AltheaDx Receives Approval From New York State For IDgenetix Tests

SAN DIEGO, Sept. 29, 2014 (GLOBE NEWSWIRE) -- AltheaDx, a commercial stage molecular diagnostics company specializing in the field of personalized medicine, today announced that IDgenetix, its pharmacogenetic (PGx) product testing portfolio, has been approved by the New York State Department of Health (NYSDOH). With this approval, AltheaDx's IDgenetix tests can now be offered in all 50 states.

"Today marks a significant milestone in the evolution of our company," said Greg Hamilton, Chief Executive Officer of AltheaDx. "The NYSDOH sets an extremely high bar for quality within the field of molecular diagnostics, and this approval, coupled with our recent CAP accreditation in which no deficiencies in our laboratory processes were found, highlights the emphasis AltheaDx places on providing U.S. healthcare providers with reliable and accurate information. Our clinical lab reports enable evidenced-based prescribing and assist providers in optimizing patient care and treatment-related outcomes. We would like to thank the NYSDOH for their diligence and responsiveness in reviewing our file."

The NYSDOH approval process for CLIA laboratory tests is among the most stringent in the U.S. The program is designed to ensure the safety and efficacy of clinical tests results offered by laboratories. During the approval process New York officials reviewed test validation data, test requisition forms, laboratory test reports, and laboratory procedure manuals. The process also included an on-site inspection of the AltheaDx laboratory which was completed with no deficiencies.

About AltheaDx

AltheaDx is a commercial stage molecular diagnostics company which focuses on enabling physicians, managed care organizations, pharmaceutical companies and other healthcare entities to make personalized therapeutic decisions for patients. AltheaDx's IDgenetix pharmacogenetic product testing portfolio addresses some of the most prevalent clinical conditions in the United States, including cardiovascular disease, neuropsychiatric disorders and pain. AltheaDx is a CAP-Accredited, CLIA-Certified laboratory located in San Diego, CA.

Forward Looking Statements

This press release may contain forward-looking statements regarding the business strategy of AltheaDx. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that could cause actual levels of activity or performance to differ materially from those expressed or implied by these forward looking statements. These statements reflect the views of AltheaDx as of the date of this press release with respect to future events and, except as required by law, it undertakes no obligation to update or revise publicly any forward looking statements, whether as a result of new information, future events or otherwise after the date of this press release.